Eximias Pharmaceutical Corporation

Eximias Pharmaceutical Corporation is a healthcare and pharmaceutical company. It focuses on the acquisition, development, and commercialization of unique oncology and infectious disease products. The company has three novel late-stage products: THYMITAQ(R) and ORATAQ(TM) for oncology, and MACROTAC(TM) for oncology and infectious diseases. THYMITAQ(R), the company’s flagship product, is currently undergoing Phase III ETHECC(C) trials for the treatment of patients with unresectable liver cancer.